Repros Therapeutics Inc. Announces That Proellex Significantly Reduces Pain In A U.S. Phase 2 Trial In Women With Moderate To Severe Endometriosis

Repros Therapeutics Inc. (NasdaqGM:RPRX) released positive results from an interim analysis of its U.S. Phase 2 endometriosis trial. The study was designed to assess the effect of Proellex on symptom control in women with endometriosis who have moderately severe to severe pain. The data show that pain, the most troublesome symptom associated with endometriosis, is statistically and clinically meaningfully reduced in one to two months of treatment compared with placebo.

More: continued here

Filed under: Pain / Anesthetics on July 16th, 2008